ImageneBio, Inc. (IMA) stock

IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$3.47+0.02 (+0.58%)

Close on Nov 13, 2026Market cap $39.39MP/E –Yield –

ImageneBio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ImageneBio's operating cash flow for the twelve months ending Sep 30, 2026 was -$40.61M. For fiscal 2025 it was -$47.84M. The highest annual figure on record is -$21.32M in fiscal 2024.

Annual operating cash flow

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$47.84M	–
FY2024	Dec 31, 2024	-$21.32M	–
FY2023	Dec 31, 2023	-$79.74M	–
FY2022	Dec 31, 2022	-$74.11M	–
FY2021	Dec 31, 2021	-$60.25M	–
FY2020	Dec 31, 2020	-$37.83M	–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$9.52M	–
Q2 FY2026	Jun 30, 2026	-$9.07M	–
Q1 FY2026	Mar 31, 2026	-$14.80M	–
Q4 FY2025	Dec 31, 2025	-$7.22M	–
Q3 FY2025	Sep 30, 2025	-$21.50M	-265.8%
Q2 FY2025	Jun 30, 2025	-$11.90M	–
Q1 FY2025	Mar 31, 2025	-$7.23M	–
Q4 FY2024	Dec 31, 2024	-$3.48M	–
Q3 FY2024	Sep 30, 2024	$12.96M	–
Q2 FY2024	Jun 30, 2024	-$12.50M	–
Q1 FY2024	Mar 31, 2024	-$18.30M	–
Q4 FY2023	Dec 31, 2023	-$21.82M	–
Q3 FY2023	Sep 30, 2023	-$20.00M	–
Q2 FY2023	Jun 30, 2023	-$18.14M	–
Q1 FY2023	Mar 31, 2023	-$19.78M	–
Q4 FY2022	Dec 31, 2022	-$17.66M	–
Q3 FY2022	Sep 30, 2022	-$17.22M	–
Q2 FY2022	Jun 30, 2022	-$19.45M	–
Q1 FY2022	Mar 31, 2022	-$19.78M	–
Q4 FY2021	Dec 31, 2021	-$13.37M	–
Q3 FY2021	Sep 30, 2021	-$17.99M	–
Q2 FY2021	Jun 30, 2021	-$15.72M	–
Q1 FY2021	Mar 31, 2021	-$13.17M	–
Q4 FY2020	Dec 31, 2020	-$12.57M	–
Q3 FY2020	Sep 30, 2020	-$7.67M	–
Q2 FY2020	Jun 30, 2020	-$7.71M	–
Q1 FY2020	Mar 31, 2020	-$9.87M	–